Today, Capgemini released its Vision and Reality Report 2009, which an in-depth look at the current global market for the life sciences industries including pharmaceutical, medical device, biotech and agribusiness. The study is based on a series of in-depth interviews with over 30 senior industry executives, representing leading pharmaceutical, medical device, biotech and agribusiness companies in Europe and North America, and the report includes responses from executives at eight of the top 10, and 12 of the top 20 global pharmaceutical companies.
According to the report, the issues facing the industry are rooted in longer term trends and can therefore be expected to persist long after the upturn, despite the fact that two thirds of life sciences companies interviewed point to a recovery within the next 24 months.
“Pharmaceutical and medical device companies will be fraught with profitability challenges for the foreseeable future, ” said Capgemini Global Life Sciences Lead Hanne Buus van der Kam. “Imminent changes to science, markets, and society, and increasing pressure from governments to make cheaper product options easily and widely available, add up to an urgent need for industry transformation that can no longer be postponed.”
